These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36216488)

  • 21. Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.
    Kokhan E; Kiyakbaev G; Medovchshikov V
    Eur J Heart Fail; 2022 Jul; 24(7):1323-1324. PubMed ID: 35238461
    [No Abstract]   [Full Text] [Related]  

  • 22. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
    Volpe M; Pedicino D
    Eur Heart J; 2022 Nov; 43(44):4614-4615. PubMed ID: 36173867
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacology of SGLT-2 inhibitors in heart failure.
    Velliou M; Polyzogopoulou E; Ventoulis I; Parissis J
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):149-160. PubMed ID: 36701817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction.
    Cavka L; Bencak Ferko U; Pitz N; Trpkovski Z; Lainscak M
    ESC Heart Fail; 2021 Aug; 8(4):2631-2636. PubMed ID: 34102028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
    Savarimuthu S; Harky A
    Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
    Rosano G; Iacoviello M; Filardi PP
    G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives.
    Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M
    Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.
    Salah HM; Verma S; Santos-Gallego CG; Bhatt AS; Vaduganathan M; Khan MS; Lopes RD; Al'Aref SJ; McGuire DK; Fudim M
    J Cardiovasc Transl Res; 2022 Oct; 15(5):944-956. PubMed ID: 35290593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology Focus: Clinical Evidence for the Use of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction.
    Berendse J; Newenhouse L
    S D Med; 2022 Jul; 75(7):328-329. PubMed ID: 36542574
    [No Abstract]   [Full Text] [Related]  

  • 34. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
    Banerjee M; Pal R; Nair K; Mukhopadhyay S
    Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.
    Tomasoni D; Fonarow GC; Adamo M; Anker SD; Butler J; Coats AJS; Filippatos G; Greene SJ; McDonagh TA; Ponikowski P; Rosano G; Seferovic P; Vaduganathan M; Voors AA; Metra M
    Eur J Heart Fail; 2022 Mar; 24(3):431-441. PubMed ID: 34894038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
    Brito D; Bettencourt P; Carvalho D; Ferreira J; Fontes-Carvalho R; Franco F; Moura B; Silva-Cardoso JC; de Melo RT; Fonseca C
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):419-436. PubMed ID: 32350793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction].
    Slíva J
    Vnitr Lek; 2022; 68(6):393-397. PubMed ID: 36316201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.